Stocktoria
Warby Parker Inc. WRBY
NYSE · stock · Ophthalmic Goods · website · IPO 2021-09-29
Warby Parker Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $871.9M | $771.3M | $669.8M | $598.1M | $540.8M | $393.7M |
| Gross profit | $470.6M | $426.8M | $365.2M | $341.1M | $317.7M | $231.9M |
| SG&A expense | $475.9M | $456.9M | $437.2M | $452.3M | $461.4M | $287.6M |
| Operating income | -$5.3M | -$30.1M | -$72.0M | -$111.2M | -$143.7M | -$55.6M |
| Income tax | $1.4M | $875,000 | $433,000 | $497,000 | $263,000 | $190,000 |
| Net income | $1.6M | -$20.4M | -$63.2M | -$110.4M | -$144.3M | -$55.9M |
| EPS (diluted) | $0.01 | $-0.17 | $-0.54 | $-0.96 | $-2.21 | $-1.05 |
| Operating cash flow | $110.8M | $98.7M | $61.0M | $10.4M | -$32.0M | $32.8M |
| Free cash flow | $43.7M | $34.7M | $7.3M | -$49.8M | -$80.5M | $12.7M |
| Cash & equivalents | $286.4M | $254.2M | $216.9M | $208.6M | $256.4M | $314.1M |
| Inventory | $44.5M | $52.3M | $62.2M | $68.8M | $57.1M | $38.5M |
| Total assets | $720.9M | $676.5M | $580.3M | $568.7M | $440.6M | $444.8M |
| Total liabilities | $353.2M | $336.4M | $278.5M | $282.1M | $154.6M | $136.3M |
| Shareholders' equity | $367.7M | $340.1M | $301.8M | $286.6M | $286.0M | -$198.1M |
Growth · year-over-year · Revenue CAGR 17.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +13.0% | +15.2% | +12.0% | +10.6% | +37.4% | — |
| Free cash flow growth | +26.0% | +374.2% | — | — | -734.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.